Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 130-143

  Hing, J ^a   Perez Ruixo, J J ^b,c   Stuyckens, K ^b   Soto Matos, A ^b   Lopez Lazaro, L ^b   Zannikos, P ^a  

^a Clinical Pharmacology Division   (United States)

^b University of Miguel Hernandez ^*  (Spain)

^c PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TRABECTEDIN;

ARTICLE; BONE MARROW; CELL COMPARTMENTALIZATION; CELL KILLING; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG INFUSION; FEEDBACK SYSTEM; HUMAN; META ANALYSIS; MODEL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; SIMULATION; STEM CELL; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; COMPUTER SIMULATION; DIOXOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LEUKOPOIESIS; MALE; MODELS, BIOLOGICAL; NEUTROPENIA; NEUTROPHILS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 37549038238     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100259     Document Type: Article

References (41)

1. Guan, Y. et al. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J. Biomol. Struc. Dyn. 10, 793-818 (1993).
2. Lau, L. et al. A phase I and pharmacokinetic study of Ecteinascidin-743 (Yondelis) in children with refractory solid tumors. Clin. Cancer Res. 11, 672-677 (2005).
3. Zewail-Foote, M. & Hurley, L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42, 2493-2497 (1999).
4. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M. & Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. USA 97, 6780-6784 (2000).
5. Takebayashi, Y. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961-966 (2001).
6. Erba, E. et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37, 97-105 (2001).
7. Izbicka, E. et al. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 9, 981-987 (1998).
8. Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organization for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576-584 (2005).
9. Trabectedin Investigator Brochure: 16 December 2004, EDMS-PSDB-3655125: 2.0.
10. Villalona-Calero, M.A. et al. A Phase I and pharmacokinetic study of Ecteinascidin-743 on a daily x5 schedule in patients with solid malignancies. Clin. Cancer Res. 8, 75-85 (2002).
11. Yovine, A. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22, 890-899 (2004).
12. Zelek, L. et al. A phase II study of Yondelis (trabectedin ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br. J. Cancer 94, 1610-1614 (2006).
13. Sessa, C. et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23, 1867-1874 (2005).
14. Minami, H., Ando, Y., Sakai, S. & Shimokata, K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J. Clin. Oncol. 13, 191-199 (1995).
15. Jakobsen, P. et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother. Pharmacol. 28, 465-469 (1991).
16. van Groeningen, C.J. et al. Pharmacokinetics of 5-fluorouracil assessed with sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48, 6956-6961 (1988).
17. Zhou, H. et al. Population pharmacokinetics/toxicodynamics (PK.TD) relationship of SAM486A in phase I studies in patients with advanced cancers. J. Clin. Pharmacol. 40, 275-283 (2000).
18. Egorin, M.J. et al. Human pharmacokinetics, excretion and metabolism of anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 46, 1513-1520 (1986).
19. Friberg, L.E. & Karlsson, M.O. Mechanistic models for myelosuppression. Invest. New Drugs 21, 183-194 (2003).
20. Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
21. Leger, F. et al. Mechanism-based models for topotecan-induced neutropenia. Clin. Pharmcol. Ther. 76, 567-578 (2004).
22. Latz, J.E., Karlsson, M.O., Rusthoven, J.J., Ghosh, A. & Johnson, R.D. A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother. Pharmacol. 57, 412-426 (2005).
23. Sandstrom, M., Lindman, H., Nygren, P., Bergh, J. & Karlsson, M.O. Model describing the relationship between pharmacokinetics and hematologic toxicity of epirubicin-docetaxel regimen in breast cancer patients. J. Clin. Oncol. 23, 413-421 (2005).
24. van Kesteren, C. et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest. New Drugs 23, 225-234 (2005).
25. Sandstrom, M., Lindman, H., Nygren, P., Johansson, M., Bergh, J. & Karlsson, M.O. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother. Pharmacol. 58, 143-156 (2006).
26. Perez-Ruixo, J.J., Zannikos, P., Hirankarn, S., Stuyckens, K., Lopez-Lazaro, L. & Owen, J.S. Population pharmacokinetic meta-analysis of trabectedin in cancer patients. Clin. Pharmacokinet. (2007, submitted).
27. Troconiz, I. et al. Phase I dose-finding study and a pharmacokinetic/ pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother. Pharmacol. 57, 727-735 (2006).
28. Kathman, S.J., Williams, D.H. & Dar, M. A Bayesian population PK-PD model of Ispinesib-induced myelosuppression. Clin. Pharmacol. Ther. 81, 88-94 (2007).
29. Ghielmini, M. et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann. Oncol. 9, 989-993 (1998).
30. Lyman, G.H., Lyman, C.H. & Agboola, O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10, 427-437 (2005).
31. Twelves, C. et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer 39, 1842-1851 (2003).
32. van Kesteren, C. et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13, 381-393 (2002).
33. Taamma, A. et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19, 1256-1265 (2001).
34. Delaloge, S. et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients. Preliminary evidence of activity. J. Clin. Oncol. 19, 1248-1255 (2001).
35. NONMEM Users Guides (eds. Beal, S.L. & Sheiner, L.B.) (GloboMax, LLC, Hanover, MD, 1992).
36. Zhang, L., Beal, S.L. & Sheiner, L.B. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J. Pharmacokinet. Pharmacodyn. 30, 387-404 (2003).
37. Testa, N.G. & Dexter, T.M. The regulation of haemopoietic cell production. In Postgraduate Hematology. 6th edn. (eds. Hoffbrand, A.V., Lewis, S.M. & Tuddenham, E.G.D.) 1-12 (Butterworth-heinemann, Oxford, UK, 1999).
38. Takani, H. et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob. Agents Chemother. 40, 988-991 (1996).
39. Wahlby, U., Matolcsi, K., Karlsson, M.O. & Jonsson, E.N. Evaluation of type I error rates when modeling ordered categorical data in NONMEM. J. Pharmacokinet. Pharmacodyn. 31, 61-74 (2004).
40. Sheiner, L.B. & Beal, S.L. Scientific commentary: some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9, 503-511 (1981).
41. Yano, Y., Beal, S.L. & Sheiner, L.B. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28, 171-192 (2001).